Literature DB >> 15678413

A mixed-effects quintile-stratified propensity adjustment for effectiveness analyses of ordered categorical doses.

Andrew C Leon1, Donald Hedeker.   

Abstract

Observational studies can be used to evaluate treatment effectiveness among patients with a broader range of illness severity than typically seen in randomized controlled clinical trials. However, there are several difficulties with observational evaluations including non-equivalent comparison groups, treatment doses and durations that vary widely, and, in longitudinal studies, multiple courses of treatment per subject. A mixed-effects approach to the propensity adjustment for non-equivalent comparison groups is described that can account for each of these perturbations. The strategy involves two stages. First, characteristics that distinguish among subjects who receive various levels of treatment are examined in a model of propensity for treatment intensity using mixed-effects ordinal logistic regression. Second, the propensity-stratified effectiveness of ordered categorical doses is compared in a mixed-effects grouped time survival model of time until recovery. The model is applied in a longitudinal, observational study of antidepressant effectiveness. Then a Monte Carlo simulation study indicates that the strategy has acceptable type I error rates and minimal bias in the estimates of treatment effectiveness. Statistical power exceeds 0.90 for an odds ratio of 1.5 with N = 250 and 500, and is acceptable for an odds ratio of 2.0 with N = 100. Nevertheless, with N = 100, the models that had high intraclass correlation coefficients had greater tendency towards non-convergence. This approach is a useful strategy for observational studies of treatment effectiveness. It is capable of adjusting for selection bias, incorporating multiple observations per subject, and comparing effectiveness of ordinal doses. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678413     DOI: 10.1002/sim.2042

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Quantile Stratification Based on a Misspecified Propensity Score in Longitudinal Treatment Effectiveness Analyses of Ordinal Doses.

Authors:  Andrew C Leon; Donald Hedeker
Journal:  Comput Stat Data Anal       Date:  2007-08-15       Impact factor: 1.681

2.  Antidepressants and risks of suicide and suicide attempts: a 27-year observational study.

Authors:  Andrew C Leon; David A Solomon; Chunshan Li; Jess G Fiedorowicz; W H Coryell; Jean Endicott; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2011-05       Impact factor: 4.384

3.  Balancing Treatment Comparisons in Longitudinal Studies.

Authors:  Sue M Marcus; Juned Siddique; Thomas R Ten Have; Robert D Gibbons; Elizabeth Stuart; Sharon-Lise T Normand
Journal:  Psychiatr Ann       Date:  2008-12-01

4.  Web-based Mindfulness-based Cognitive Therapy for reducing residual depressive symptoms: An open trial and quasi-experimental comparison to propensity score matched controls.

Authors:  Sona Dimidjian; Arne Beck; Jennifer N Felder; Jennifer M Boggs; Robert Gallop; Zindel V Segal
Journal:  Behav Res Ther       Date:  2014-09-18

5.  Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders.

Authors:  Andrew C Leon; Jess G Fiedorowicz; David A Solomon; Chunshan Li; William H Coryell; Jean Endicott; Jan Fawcett; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

6.  Total hip arthroplasty: leg length inequality impairs functional outcomes and patient satisfaction.

Authors:  Christoph Röder; Raphael Vogel; Lukas Burri; Daniel Dietrich; Lukas P Staub
Journal:  BMC Musculoskelet Disord       Date:  2012-06-11       Impact factor: 2.362

Review 7.  Evaluation of psychiatric interventions in an observational study: issues in design and analysis.

Authors:  Andrew C Leon
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.